WELCOME to the new ModernAesthetics.com

You can find all AestheticsWire, MATV, and Modern Aesthetics® content here!

MA push banner logos
search Created with Sketch.
search Created with Sketch.

Advertisement

Topic: Energy-based Devices

MATV News: Revance to Bring Teoxane Fillers to US; Allergan Introduces Alle; More thumbnail
Play Button

MATV News: Revance to Bring Teoxane Fillers to US; Allergan Introduces Allē More

Series: MATV News | January 17, 2020

Revance enters an exclusive distribution deal with Teoxane to bring RHA line of fillers to US Market, Allergan revamps its customer loyalty rewards program, and findings of a new study may indicate what’s driving increases in body contouring procedures. 

Watch Video

News | January 9, 2020

Revian: USPTO Grants Patent for Biostimulatory Approach

The United States Patent and Trademark Office (USPTO) has awarded to Revian Inc. U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the...

Read More
Device Talk: Can We Address Cellulite? thumbnail
Play Button

Device Talk: Can We Address Cellulite?

Series: Device Talk | December 16, 2019

The architecture of cellulite leads to its unique appearance and complex treatment. Advancements in device technology allow for better results than ever for dimpling, sagging, and other features of the disease, say Mathew Avram, MD and Jeremy Green, MD. Combination approaches may yield best outcomes.

Watch Video
MATV News: Revance DAXI News; CSF 2019 Highlights; MiRing Device; ISAPS Stats thumbnail
Play Button

MATV News: Revance DAXI News; CSF 2019 Highlights; miRing Device; ISAPS Stats

Series: MATV News | December 16, 2019

Revance Therapeutics long-acting neuromodulator is now one step closer to FDA approval, Dr. Joel L. Cohen hosts coverage of Cosmetic Surgery Forum, and a new medical device is catching some buzz in the medical community. Plus, a look at annual statistics from the International Society of Aesthetic Plastic Surgery. 

Watch Video

News | October 23, 2019

Merz: Cellfina for Cellulite Cleared for 5 Years of Benefit

The FDA has cleared a new indication statement for Cellfina that shows the benefits of treatment last for five years, an increase from the previous three-year indication. Cellfina from Merz demonstrated five-year improvement in the...

Read More

Advertisement

The Latest in Energy-based Devices

Advertisement

Advertisement

View more